acetohexamide acetohexamide acetohexamide (trade name dymelor) is a first-generation sulfonylurea medication used to treat diabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone. not to be confused with acetazolamide. acetohexamideclinical datatrade namesdymelorahfs/drugs.commicromedex detailed consumer informationmedlineplusa602021atc codea10bb31 (who) pharmacokinetic dataprotein binding90%identifiers iupac name 1--3-cyclohexylurea 4-acetyl-n-(cyclohexylcarbamoyl)benzenesulfonamide cas number968-81-0 ypubchem cid1989iuphar/bps6793drugbankdb00414 ychemspider1912 yuniiqgc8w08i6ikeggd00219 ychebichebi:28052 ychemblchembl1589 ycomptox dashboard (epa)dtxsid7020007 echa infocard100.012.301 chemical and physical dataformulac15h20n2o4smolar mass324.40 g·mol−13d model (jsmol)interactive imagemelting point188 to 190 °c (370 to 374 °f) smiles o=c(nc1ccccc1)ns(=o)(=o)c2ccc(c(=o)c)cc2 inchi inchi=1s/c15h20n2o4s/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13h,2-6h2,1h3,(h2,16,17,19) ykey:vgzsupcwncwdan-uhfffaoysa-n y (verify) mechanism of action acetohexamide bind to an atp-sensitive k+ (katp) channel on the cell membrane of pancreatic beta cells. this inhibits the out flux of potassium, which causes the membrane potential to become more positive. this depolarization in turn opens voltage-gated calcium channels. the rise in intracellular calcium leads to increased fusion of insulin granulae with the cell membrane, and therefore increased secretion of insulin. risks oral hypoglycemic drugs, including acetohexamide, have been associated with increased cardiovascular mortality. talk to your doctor about the possible risks, benefits, and alternatives of using this drug for your condition.